Venous Thrombosis in Acquired Hemophilia: The Complex Management of Competing Pathologies

 

 Permissions and Reprints

Abstract

Introduction Venous thrombosis is rare in the setting of factor VIII (FVIII) deficiency. Cases of deep vein thrombosis (DVT) have been described in hemophiliacs after recent major surgery, or in association with the administration of FVIII concentrate and activated prothrombin complex concentrates, but occurrence of spontaneous DVT is even more uncommon.

Aim We describe the challenging management of extensive DVT in a patient with acquired hemophilia A with concurrent hemorrhagic manifestations and review similar published cases.

Methods We summarize a series of 10 cases with the following demographics: 6 males and 4 females; median age at presentation of 65 (21–80); mean inhibitor titer of 68.5 Bethesda Units (BU 1.9 to BU 350).

Results Four cases were idiopathic and six had associated conditions (cancer [two cases], recent pregnancy [two cases], and recent surgery [two cases]). Three cases had an inferior vena cava filter inserted for acute lower limb DVT/pulmonary embolism. Inhibitor eradication was achieved with high-dose steroids with or without cyclophosphamide, and adjunct Rituximab administration was used in three cases. One patient received concurrent therapeutic plasma exchange (TPE). Inhibitor eradication was fastest with concurrent TPE at 6 days (range: 6–733 days). The 30-day survival was 90%.

Conclusions There was adequate response of inhibitors to immunosuppression with steroids and cyclophosphamide therapy. For more refractory disease, Rituximab is emerging as a beneficial and cost-effective adjunct with better rates of complete remission, and the threshold for its use may be lowered in this complex cohort with dual competing pathologies.

• References

• 1 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (02) 250-255
  CrossrefPubMedGoogle Scholar
• 2 Baudo F, Collins P, Huth-Kühne A. , et al; EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120 (01) 39-46
  PubMedGoogle Scholar
• 3 Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128 (02) 178-184
  CrossrefPubMedGoogle Scholar
• 4 Girolami A, Scandellari R, Zanon E, Sartori R, Girolami B. Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J Thromb Thrombolysis 2006; 21 (03) 279-284
  CrossrefPubMedGoogle Scholar
• 5 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149 (06) 824-833
  CrossrefPubMedGoogle Scholar
• 6 Tsai AW, Cushman M, Rosamond WD. , et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113 (08) 636-642
  CrossrefPubMedGoogle Scholar
• 7 Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388 (10063): 3060-3073
  CrossrefPubMedGoogle Scholar
• 8 Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009; 23 (05) 225-229
  CrossrefPubMedGoogle Scholar
• 9 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134 (05) 1087-1097
  PubMedGoogle Scholar
• 10 van 't Veer C, Hackeng TM, Delahaye C, Sixma JJ, Bouma BN. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994; 84 (04) 1132-1142
  CrossrefPubMedGoogle Scholar
• 11 Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66 (04) 464-467
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Erhardtsen E, Ezban M, Madsen MT. , et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6 (05) 388-394
  CrossrefPubMedGoogle Scholar
• 13 Deitcher SR, Carman TL, Kottke-Marchant K. Simultaneous deep venous thrombosis and acquired factor VIII inhibitor. Clin Appl Thromb Hemost 2002; 8 (04) 375-379
  CrossrefPubMedGoogle Scholar
• 14 Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75 (05) 1069-1073
  CrossrefPubMedGoogle Scholar
• 15 Siow BL, Nadarajah K, Jayaratnam FJ. Acquired haemophilia. A case report. Singapore Med J 1982; 23 (06) 328-330
  PubMedGoogle Scholar
• 16 Poli D, Francois C, Bini G, Caciolli S, Prisco D. Acquired hemophilia mimicking deep vein thrombosis. Report of three cases. Ann Ital Med Int 1997; 12: 166-168
  PubMedGoogle Scholar
• 17 Spencer A, Pearce MI, Ames PR. Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time. Thromb J 2011; 9: 16
  CrossrefPubMedGoogle Scholar
• 18 Paudel R, Dominguez LW, Dogra P, Suman S, Badin S, Wasserman C. A hematological menace: multiple venous thrombosis complicated by acquired factor VIII deficiency. Am J Case Rep 2016; 17: 214-218
  CrossrefPubMedGoogle Scholar
• 19 Maral S, Bakanay SM, Dilek I. Acquired hemophilia with thrombosis in a cancer patient: an unusual presentation. Blood Coagul Fibrinolysis 2018; 29 (01) 129-130
  CrossrefPubMedGoogle Scholar
• 20 Wool GD, Chapel D, Treml A, Miller JL. Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism. Transfusion 2017; 57 (07) 1827-1832
  CrossrefPubMedGoogle Scholar
• 21 Gaitini D. Multimodality imaging of the peripheral venous system. Int J Biomed Imaging 2007; 2007: 54616
  PubMedGoogle Scholar
• 22 Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg 2003; 69 (08) 654-659
  PubMedGoogle Scholar
• 23 Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120 (04) 891-899
  PubMedGoogle Scholar
• 24 Augustsson C, Persson E. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia. Blood 2014; 124 (20) 3172-3174
  PubMedGoogle Scholar
• 25 Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119 (02) 578
  CrossrefPubMedGoogle Scholar
• 26 D'arena G, Grandone E, Di Minno MN, Musto P, Di Minno G. The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfus 2016; 14 (02) 255-261
  PubMedGoogle Scholar